Product Code: IRTNTR21998
About this market
Patients and physician's willingness to switch to biosimilars is expected to drive growth in the market. Majority of physicians, especially rheumatologists, preferred to prescribe a bio-originator instead of biosimilar as the first line therapy for the treatment. However, the physician and patients are very much willing to shift to biosimilars. Technavio's analysts have predicted that the biosimilars market will register a CAGR of almost 35% by 2022.
Market Overview
Price advantage of biosimilars over biologics
High cost of biologics reduces patient access to these products and increases the total healthcare costs. The reason for less cost of biosimilar can be sue to the smaller number of clinical trials for a biosimilar when compared with original biologic.
Market access barriers for biosimilars
To compete with biologics and to get entry into the market, the biosimilars are facing challenge. The first and foremost challenge is sophisticated manufacturing process associated with biosimilars.
For the detailed list of factors that will drive and challenge the growth of the biosimilars market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the patients and physician's willingness to switch to biosimilars and the price advantage of biosimilars over biologics, will provide considerable growth opportunities to biosimilars manufactures. Amgen, Biogen, Merck, Novartis, and Pfizer are some of the major companies covered in this report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 08: MARKET SEGMENTATION BY APPLICATION
- Segmentation by application
- Comparison by application
- Oncology and hematology - Market size and forecast 2017-2022
- Endocrinology - Market size and forecast 2017-2022
- Immunology - Market size and forecast 2017-2022
- Nephrology - Market size and forecast 2017-2022
- Market opportunity by application
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Americas - Market size and forecast 2017-2022
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Patients and physician's willingness to switch to biosimilars
- Therapeutic interchangeability regulations for biosimilars across countries
- Biosimilar "patent dance"
- Many originator companies entering the biosimilar market
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen
- Biogen
- Merck
- Novartis
- Pfizer
PART 16: APPENDIX
- List of abbreviations
- Exhibit 01: Parent market
- Exhibit 02: Global pharmaceuticals market
- Exhibit 03: Market characteristics
- Exhibit 04: Market segments
- Exhibit 05: Biosimilars approved by US FDA in 2017 and 2018
- Exhibit 06: Biosimilars approved by EMA in 2017 and 2018
- Exhibit 07: Market definition - Inclusions and exclusions checklist
- Exhibit 08: Market size 2017
- Exhibit 09: Validation techniques employed for market sizing 2017
- Exhibit 10: Global - Market size and forecast 2017-2022 ($ bn)
- Exhibit 11: Global - Year-over-year growth 2018-2022 (%)
- Exhibit 12: Five forces analysis 2017
- Exhibit 13: Five forces analysis 2022
- Exhibit 14: Bargaining power of buyers
- Exhibit 15: Bargaining power of suppliers
- Exhibit 16: Threat of new entrants
- Exhibit 17: Threat of substitutes
- Exhibit 18: Threat of rivalry
- Exhibit 19: Market condition - Five forces 2017
- Exhibit 20: Application - Market share 2017-2022 (%)
- Exhibit 21: Comparison by application
- Exhibit 22: Oncology and hematology - Market size and forecast 2017-2022 ($ bn)
- Exhibit 23: Oncology and hematology - Year-over-year growth 2018-2022 (%)
- Exhibit 24: Endocrinology - Market size and forecast 2017-2022 ($ bn)
- Exhibit 25: Endocrinology - Year-over-year growth 2018-2022 (%)
- Exhibit 26: Immunology - Market size and forecast 2017-2022 ($ bn)
- Exhibit 27: Immunology - Year-over-year growth 2018-2022 (%)
- Exhibit 28: Nephrology - Market size and forecast 2017-2022 ($ bn)
- Exhibit 29: Nephrology - Year-over-year growth 2018-2022 (%)
- Exhibit 30: Market opportunity by application
- Exhibit 31: Customer landscape
- Exhibit 32: Global - Market share by geography 2017-2022 (%)
- Exhibit 33: Regional comparison
- Exhibit 34: EMEA - Market size and forecast 2017-2022 ($ bn)
- Exhibit 35: EMEA - Year-over-year growth 2018-2022 (%)
- Exhibit 36: Top 3 countries in EMEA
- Exhibit 37: APAC - Market size and forecast 2017-2022 ($ bn)
- Exhibit 38: APAC - Year-over-year growth 2018-2022 (%)
- Exhibit 39: Top 3 countries in APAC
- Exhibit 40: Americas - Market size and forecast 2017-2022 ($ bn)
- Exhibit 41: Americas - Year-over-year growth 2018-2022 (%)
- Exhibit 42: Top 3 countries in Americas
- Exhibit 43: Market opportunity
- Exhibit 44: Vendor landscape
- Exhibit 45: Landscape disruption
- Exhibit 46: Vendor classification
- Exhibit 47: Market positioning of vendors
- Exhibit 48: Amgen - Overview
- Exhibit 49: Amgen - Business segments
- Exhibit 50: Amgen - Organizational developments
- Exhibit 51: Amgen - Geographic focus
- Exhibit 52: Amgen - Key offerings
- Exhibit 53: Biogen - Overview
- Exhibit 54: Biogen - Business segments
- Exhibit 55: Biogen - Organizational developments
- Exhibit 56: Biogen - Geographic focus
- Exhibit 57: Biogen - Key offerings
- Exhibit 58: Merck - Overview
- Exhibit 59: Merck - Business segments
- Exhibit 60: Merck - Organizational developments
- Exhibit 61: Merck - Geographic focus
- Exhibit 62: Merck - Segment focus
- Exhibit 63: Merck - Key offerings
- Exhibit 64: Novartis - Overview
- Exhibit 65: Novartis - Business segments
- Exhibit 66: Novartis - Organizational developments
- Exhibit 67: Novartis - Geographic focus
- Exhibit 68: Novartis - Segment focus
- Exhibit 69: Novartis - Key offerings
- Exhibit 70: Pfizer - Overview
- Exhibit 71: Pfizer - Business segments
- Exhibit 72: Pfizer - Organizational developments
- Exhibit 73: Pfizer - Geographic focus
- Exhibit 74: Pfizer - Segment focus
- Exhibit 75: Pfizer - Key offerings
